Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.

[1]  R. Labianca,et al.  Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  K. Nackaerts,et al.  Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  C. Obasaju,et al.  Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. , 2007, Lung cancer.

[4]  M. Metintaş,et al.  Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. García-Carbonero,et al.  Systemic chemotherapy in the management of malignant peritoneal mesothelioma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  C. Obasaju,et al.  Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  A. Ceribelli,et al.  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Obasaju,et al.  Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. , 2005, Clinical lung cancer.

[9]  Robert M. White,et al.  Pemetrexed in malignant pleural mesothelioma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  D. Christiani,et al.  Epidemiology, biologic behavior, and natural history of mesothelioma. , 2004, Thoracic surgery clinics.

[11]  Richard Pazdur,et al.  FDA drug approval summaries: pemetrexed (Alimta). , 2004, The oncologist.

[12]  Bertram Price,et al.  Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. , 2004, American journal of epidemiology.

[13]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Giaccone,et al.  The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). , 2003, European journal of cancer.

[15]  Duc Thanh Le,et al.  Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma , 2003, Cancer investigation.

[16]  K. Geisinger,et al.  Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma , 2001, The American surgeon.

[17]  J. Shamash,et al.  Phase II study of vinorelbine in patients with malignant pleural mesothelioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[19]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[20]  J. Herndon,et al.  Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma , 1999, Cancer.

[21]  J. Dempsey,et al.  Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. , 1999, Seminars in oncology.

[22]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[23]  A. Musk,et al.  Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Herndon,et al.  Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Herndon,et al.  Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Stenwig,et al.  High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. , 1992, British Journal of Cancer.

[27]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[28]  K. Antman.  Clinical presentation and natural history of benign and malignant mesothelioma. , 1981, Seminars in oncology.